Shanghai Escugen Biotechnology Co., Ltd
7 clinical trials · Sponsor
◉ Watch Shanghai Escugen Biotechnology Co., Ltd
| Record | Firm | Date |
|---|---|---|
| A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus (NCT07760155) | Shanghai Escugen Biotechnology Co., Ltd | 2026-09-01 |
| A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome (NCT07375524) | Shanghai Escugen Biotechnology Co., Ltd | 2026-03-01 |
| A First-in-Human Phase I Study of ESG206 in Subjects With B-cell Lymphoid Malignancies (NCT05263739) | Shanghai Escugen Biotechnology Co., Ltd | 2025-12-01 |
| Study of ESG406 in Adults With Solid Tumors (NCT06979674) | Shanghai Escugen Biotechnology Co., Ltd | 2025-06-04 |
| A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies (NCT05822843) | Shanghai Escugen Biotechnology Co., Ltd | 2023-08-02 |
| Study of ESG401 in Adults With Solid Tumors (NCT04892342) | Shanghai Escugen Biotechnology Co., Ltd | 2021-09-14 |
Track Shanghai Escugen Biotechnology Co., Ltd automatically
Every clearance here is in the API, with alerts when new ones post.